Evosep aims to improve quality of life and patient care by radically innovating protein based clinical diagnostics. We will make sample preparation and separation for mass spectrometry analysis 100 times more robust and 10 times faster to enable truly large cohort studies and provide the foundation for precision medicine.
Biomarker tests have become an important tool in clinical diagnostics. The PSA test evaluates the risk for prostate cancer, and inflammatory and myocardial panels save lives when performed fast enough. Still biomarkers, especially protein biomarkers, are not yet used to their full potential. While novel approaches employ mass spectrometry instead of immunoassay detection, one bottleneck remains: the need for robust, fast, and efficient sample preparation.
Almost 50 years after their inception, immunoassays (IAs) are still the predominant method in biomarker diagnostics. IAs are used to detect pregnancies, infections, allergies, and many other health events in our lives. But for how much longer?
Biomarker tests have become an important tool in clinical diagnostics. The PSA test evaluates the risk for cancer, and inflammatory and myocardiac panels save lives when performed fast enough. Still biomarkers, especially protein biomarkers, are not used to their full potential. While novel approaches employ mass spectrometry instead of immunoassay detection, one bottleneck remains: the need for robust, fast, and efficient sample preparation.
